<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791648</url>
  </required_header>
  <id_info>
    <org_study_id>081238</org_study_id>
    <nct_id>NCT00791648</nct_id>
  </id_info>
  <brief_title>Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery</brief_title>
  <official_title>Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim1a: Statin naive patient's scheduled for cardiac surgery will be randomized to 80mg
      atorvastatin or placebo on the day prior to surgery and then 40mg daily thereafter until
      hospital discharge to test the hypothesis that short-term atorvastatin use decreases:

        1. acute kidney injury following cardiac surgery.

        2. postoperative delirium following cardiac surgery.

      Aim1b: Patients using statins preoperatively will be randomized to atorvastatin 80mg or
      placebo on day of surgery and 40mg or placebo on postop day 1 with resumption of preoperative
      statin therapy on postop day 2 to test the hypothesis that short-term atorvastatin use
      decreases:

        1. acute kidney injury following cardiac surgery.

        2. postoperative delirium following cardiac surgery.

      Endpoints include glomerular filtration, urine and plasma markers of renal dysfunction,
      markers of oxidative stress, mitochondrial function, systemic inflammatory markers, delirium,
      dialysis, stroke, myocardial infarction, time to extubation, ICU length of stay, and death.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Acute Kidney Injury</measure>
    <time_frame>postoperative day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Delirium</measure>
    <time_frame>while in ICU (about 2 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Dialysis</measure>
    <time_frame>while in ICU (about 2 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Markers of Renal Injury</measure>
    <time_frame>at randomization, anesthesia induction, 30 minutes into cardiopulm bypass (CPB), after CPB, ICU admission, 6 hours postop, 12 hours postop, and Post op Day (POD) 1, 2, 3.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Markers of Inflammation</measure>
    <time_frame>at randomization, anesthesia induction, 30 minutes into cardiopulmonary bypass (CPB), after CPB, ICU admission, 6 hours postop, and POD 1, 2, 3.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Enzyme: Aspartate Aminotransferase Level</measure>
    <time_frame>postoperative day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stroke</measure>
    <time_frame>while in ICU (about 2 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Died</measure>
    <time_frame>until postoperative hospital discharge (about 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and Urine Markers of Oxidative Stress (f2-Isoprostanes, Isofurans)</measure>
    <time_frame>at randomization, anesthesia induction, 30 minutes into cardiopulmonary bypass (CPB), after CPB, ICU admission, 6 hours postop, and POD 1, 2, 3.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>at randomization, anesthesia induction, 30 minutes into cardiopulmonary bypass (CPB), after CPB, ICU admission, 6 hours postop, and POD 1, 2, 3.</time_frame>
    <description>mtDNA copy number, lactate / pyruvate ratio, PGC-1alpha RNA expression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">653</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Post-Operative Delirium</condition>
  <condition>Icu Delirium</condition>
  <condition>Acute Renal Failure</condition>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
    <arm_group_label>statin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  open heart surgery

        Exclusion Criteria:

          -  acute coronary syndrome with troponin leak or unrelenting angina

          -  liver dysfunction (transaminases 2x normal)

          -  history of myopathy or liver dysfunction on prior statin therapy

          -  use of potent CYP3A4 inhibitors such as antifungal azoles, macrolide antibiotics, HIV
             protease inhibitors, and nefazodone.

          -  pregnancy or breast feeding

          -  cyclosporine use

          -  dialysis

          -  history of kidney transplant

          -  fibrate users who cannot stop fibrate use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic T. Billings, IV, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <results_first_submitted>November 11, 2016</results_first_submitted>
  <results_first_submitted_qc>January 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Frederic T Billings IV</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>aki</keyword>
  <keyword>delirium</keyword>
  <keyword>statin</keyword>
  <keyword>short-term</keyword>
  <keyword>cardiac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>36 patients consented patients were excluded prior to randomization
14 withdrew, 12 did not require surgery, 4 had unreported baseline live dysfunction, 2 developed acute coronary syndrome, 2 had statin intolerance, 1 died prior to study intervention and surgery, 1 enrolled in another drug study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Statin</title>
          <description>atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="307"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Statin</title>
          <description>atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="308"/>
            <count group_id="B2" value="307"/>
            <count group_id="B3" value="615"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="49" upper_limit="81"/>
                    <measurement group_id="B2" value="67" lower_limit="51" upper_limit="81"/>
                    <measurement group_id="B3" value="66" lower_limit="49" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="307"/>
                    <measurement group_id="B3" value="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Kidney Injury</title>
        <time_frame>postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Statin</title>
            <description>atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Kidney Injury</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.75</p_value>
            <method>Pearson x2</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Delirium</title>
        <time_frame>while in ICU (about 2 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Statin</title>
            <description>atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Delirium</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.56</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Dialysis</title>
        <time_frame>while in ICU (about 2 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Statin</title>
            <description>atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Dialysis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.71</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Markers of Renal Injury</title>
        <time_frame>at randomization, anesthesia induction, 30 minutes into cardiopulm bypass (CPB), after CPB, ICU admission, 6 hours postop, 12 hours postop, and Post op Day (POD) 1, 2, 3.</time_frame>
        <posting_date>04/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Markers of Inflammation</title>
        <time_frame>at randomization, anesthesia induction, 30 minutes into cardiopulmonary bypass (CPB), after CPB, ICU admission, 6 hours postop, and POD 1, 2, 3.</time_frame>
        <posting_date>07/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Enzyme: Aspartate Aminotransferase Level</title>
        <time_frame>postoperative day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Statin</title>
            <description>atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Enzyme: Aspartate Aminotransferase Level</title>
          <units>units/liter</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="25" upper_limit="105"/>
                    <measurement group_id="O2" value="52" lower_limit="27" upper_limit="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.11</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stroke</title>
        <time_frame>while in ICU (about 2 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Statin</title>
            <description>atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stroke</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.06</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Died</title>
        <time_frame>until postoperative hospital discharge (about 7 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Statin</title>
            <description>atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Died</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.39</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma and Urine Markers of Oxidative Stress (f2-Isoprostanes, Isofurans)</title>
        <time_frame>at randomization, anesthesia induction, 30 minutes into cardiopulmonary bypass (CPB), after CPB, ICU admission, 6 hours postop, and POD 1, 2, 3.</time_frame>
        <posting_date>07/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitochondrial Function</title>
        <description>mtDNA copy number, lactate / pyruvate ratio, PGC-1alpha RNA expression</description>
        <time_frame>at randomization, anesthesia induction, 30 minutes into cardiopulmonary bypass (CPB), after CPB, ICU admission, 6 hours postop, and POD 1, 2, 3.</time_frame>
        <posting_date>07/2018</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First 10 post-op days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Statin</title>
          <description>atorvastatin: Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="308"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolytic Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Coagulapathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Idiopathic Thrombocytopenia Purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="308"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Severe Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Severe Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall with Factured Hip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Intra-operative Injury to Blood Vessel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Severe Respiratory Distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sternal Dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Peripheral Vascular Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="308"/>
                <counts group_id="E2" subjects_affected="307" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="215" subjects_affected="49" subjects_at_risk="308"/>
                <counts group_id="E2" events="190" subjects_affected="42" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1032" subjects_affected="188" subjects_at_risk="308"/>
                <counts group_id="E2" events="1073" subjects_affected="192" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Vasoplegia</sub_title>
                <counts group_id="E1" events="342" subjects_affected="120" subjects_at_risk="308"/>
                <counts group_id="E2" events="357" subjects_affected="118" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Decreased Cardiac Output</sub_title>
                <description>Cardiac Output was only measured in patients with a pulmonary artery catheter</description>
                <counts group_id="E1" events="643" subjects_affected="187" subjects_at_risk="308"/>
                <counts group_id="E2" events="623" subjects_affected="194" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lactic Acidosis</sub_title>
                <counts group_id="E1" events="194" subjects_affected="55" subjects_at_risk="308"/>
                <counts group_id="E2" events="202" subjects_affected="59" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminemia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="308"/>
                <counts group_id="E2" events="46" subjects_affected="39" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="125" subjects_affected="50" subjects_at_risk="308"/>
                <counts group_id="E2" events="117" subjects_affected="52" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="513" subjects_affected="141" subjects_at_risk="308"/>
                <counts group_id="E2" events="522" subjects_affected="140" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1608" subjects_affected="183" subjects_at_risk="308"/>
                <counts group_id="E2" events="1537" subjects_affected="172" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frederic Billings</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-343-6268</phone>
      <email>frederic.t.billings@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

